Latest Breaking News On - Kynos therapeutics - Page 1 : comparemela.com

Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement

Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofSue charlesJonathan savidgeKynos therapeutics ltdUniversity of edinburghIp groupTherapeutics ltdInnovate united kingdomKynos therapeuticsEpidarex capitalScottish enterpriseInnovate united

Kynos Therapeutics unveils KMO inhibitor trial results

Kynos Therapeutics Ltd, based in Edinburgh, UK, focuses on developing small molecule kynurenine 3-monooxygenase (KMO) inhibitors for inflammatory disorders.

United kingdomJonathan savidgeDamian moleKynos therapeuticsInnovate united kingdomClinical developmentPreclinical researchAtient centricityPis active pharmaceutical ingredientsData managementHasei iiClinical trialPharmaceutical industryInflammatory diseases

Edinburgh Innovations | Positive trial results for Kynos…

Edinburgh Innovations | Positive trial results for Kynos…
ed.ac.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ed.ac.uk Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomScott websterJonathan savidgeSusan bodieCentre for cardiovascular researchUniversity of edinburghUniversity of edinburgh centre for inflammation researchInflammation researchCardiovascular researchDamian moleProfessor scott websterBusiness developmentVeterinary medicineKynos therapeuticsInnovate united kingdom

Edinburgh Innovations | Kynos clinical trials begin

University of Edinburgh biotechnology spinout Kynos Therapeutics Ltd has announced that dosing is underway in a first in-human phase I trial of its lead drug candidate, KNS366.

City ofUnited kingdomSusan bodieJonathan savidgeUniversity of edinburgh centre for inflammation researchUniversity of edinburghInflammation researchDamian moleKynos therapeuticsEdinburgh innovationsBusiness developmentVeterinary medicineInnovate united kingdom

Kynos Therapeutics announces a first-in-human Phase I study of its novel small molecule KMO inhibitor, KNS366, is underway

Kynos Therapeutics announces a first-in-human Phase I study of its novel small molecule KMO inhibitor, KNS366, is underwayEdinburgh UK, 18 May 2023 - Kynos Therapeutics Ltd, a biotechnology company developing a portfolio of first in class kynurenine 3-monooxygenase (KMO) inhibitors, today announces that dosing is un.

United kingdomJonathan savidgeKynos therapeutics ltdKynos therapeuticsTherapeutics ltdInnovate united kingdom